(Press-News.org) Insilico Medicine (“Insilico”) is featured in the new BBC StoryWorks-produced film series Nature’s Building Blocks made in conjunction with the Biotechnology Innovation Organization (BIO). Through 29 short films, the series showcases science innovations and cutting-edge technological advances that are poised to dramatically improve human life.
Insilico, a generative artificial intelligence (AI)-driven drug discovery company, is featured in a segment focused on democratizing and accelerating new therapeutics with the use of AI.
In the mid-2000s, deep neural networks began outperforming humans in image and text recognition, says Insilico founder and CEO Alex Zhavoronkov, PhD, in the segment. Those technological advances provided an opportunity for Insilico to train AI on aging and disease and create its powerful end-to-end platform called Pharma.AI.
Pharma.AI can process and analyze massive quantities of data to identify new targets for drugs, design new drug-like molecules, and even predict the outcome of clinical trials. Insilico has used this platform to produce a robust pipeline of therapeutics – 31 programs for 29 drug targets in disease areas including cancer, fibrosis, chronic kidney disease, and COVID-19. Its lead drug for the devastating lung disease idiopathic pulmonary fibrosis is the first AI-discovered and generative AI-designed drug to reach human clinical trials.
The BBC filmed Zhavoronkov on site in the Company’s Hong Kong headquarters where application scientists work on Insilico’s AI-enabled biological target discovery engine, PandaOmics, which is used to discover therapeutic targets and accelerate drug discovery and development for pharma companies.
“What AI really is, is mathematics and neuroscience,” Zhavoronkov says in the episode. “To me, AI represents hope.”
Other topics explored in the series include gene editing, synthetic DNA, and antibody therapy.
“The work of biotechnology is more than just vaccines and medications,” says Hilary Stiss, Director of International Affairs for BIO. “It’s defining today’s medicine and transforming the way we heal, feed, and fuel our world.”
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
END
Insilico Medicine featured in BBC-produced series on biotech breakthroughs
2023-03-29
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
A reconstruction of prehistoric temperatures for some of the oldest archaeological sites in North America
2023-03-29
Scientists often look to the past for clues about how Earth’s landscapes might shift under a changing climate, and for insight into the migrations of human communities through time. A new study offers both by providing, for the first time, a reconstruction of prehistoric temperatures for some of the first known North American settlements.
The study, published in Quaternary Science Reviews, uses new techniques to examine the past climate of Alaska’s Tanana Valley. With a temperature record that reaches back 14,000 years, researchers now have ...
Mimicking biological enzymes may be key to hydrogen fuel production
2023-03-29
CHAMPAIGN, Ill. — An ancient biological enzyme known as nickel-iron hydrogenase may play a key role in producing hydrogen for a renewables-based energy economy, researchers said. Careful study of the enzyme has led chemists from the University of Illinois Urbana-Champaign to design a synthetic molecule that mimics the hydrogen gas-producing chemical reaction performed by the enzyme.
The researchers reported their findings in the journal Nature Communications.
Currently, industrial hydrogen is usually produced by separating hydrogen gas molecules from oxygen atoms in water using a process called ...
Ochsner Health named 2023 Gallup Exceptional Workplace Award Winner
2023-03-29
NEW ORLEANS, LOUISIANA— Ochsner Health, Louisiana’s largest nonprofit, academic, multi-specialty, healthcare delivery system, has received the 2023 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world.
After another year of unpredictability in the workplace, Gallup found that Ochsner Health continued to put their employees’ engagement at the center of their business strategy, embedding engagement into their very culture.
“Our employees are the reason for the culture of positive engagement at Ochsner Health. From physicians and providers to clinical ...
Heart attack study could change the game in regenerative medicine
2023-03-29
LA JOLLA, CALIF. Mar 29, 2023 - Sanford Burnham Prebys researchers have identified a group of proteins that could be the secret to cellular reprogramming, an emerging approach in regenerative medicine in which scientists transform cells to repair damaged or injured body tissues. The researchers were able to reprogram damaged heart cells to repair heart injuries in mice following a heart attack. The findings, which appear in the journal Nature Communications, could one day transform the way we treat a variety of diseases, including cardiovascular disease, Parkinson’s ...
Do your headaches happen at the same time of day?
2023-03-29
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, MARCH 29, 2023
MINNEAPOLIS – Both cluster headache and migraine have strong links to the circadian system, the internal clock that regulates body processes, according to a meta-analysis published in the March 29, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The meta-analysis included all available studies on cluster headache and migraine that included circadian features. This included information on the timing of headaches during ...
Imaging brain connections can predict improvements in obsessive-compulsive disorder patients after deep brain stimulation
2023-03-29
Deep brain stimulation (DBS) is a promising therapy for treatment-resistant obsessive-compulsive disorder (OCD). A first-of-its-kind collaborative study led by researchers at Texas Children’s Hospital, Baylor College of Medicine, and Brigham & Women’s Hospital has found that mapping neural connections in the brains of OCD patients offers key insights that explain the observed improvements in their clinical outcomes after DBS. The study was published in Biological Psychiatry.
Neuropsychiatric disorders such as obsessive-compulsive ...
Lab-made antibodies offer potential cure for yellow fever
2023-03-29
PORTLAND, Oregon -- New research from Oregon Health & Science University and collaborators indicates lab-made antibodies may be able to cure people infected with yellow fever, a virus for which there is no treatment.
The natural immune response to invading pathogens normally involves making protective proteins called antibodies. A study published today in Science Translational Medicine suggests that a single monoclonal antibody infusion can strengthen the body’s fight against yellow fever.
In the study, the yellow fever virus was undetectable in all animals that received monoclonal antibody infusions after being exposed to the virus.
“Two ...
Evermed, ACC launch ACC Anywhere, the 'Netflix of Cardiology'
2023-03-29
Evermed and the American College of Cardiology (ACC) have announced the launch of ACC Anywhere, a new content hub that provides cardiologists around the world with on-demand access to the latest clinical knowledge. The hub contains original content from five conferences including ACC’s 2022 and 2023 Annual Scientific Session, with additional conferences to be added in the future.
Evermed was selected to collaborate with ACC due to its advanced AI-powered recommender engine and its ability to effectively deliver medical education content 365 days per year. In addition, Evermed’s technology will help drive yearlong engagement to ensure that users are able ...
The clinical presentation of IDDMSSD syndrome is likely associated with the molecular location of the mutation in the PAK1 gene
2023-03-29
A recent study from Texas Children’s Hospital and Baylor College of Medicine has expanded the clinical spectrum of a new epileptic disorder called Intellectual Developmental Disorder with Macrocephaly, Seizures, and Speech Delay (IDDMSSD) with the identification of the first recurrently affected residue identified in the protein kinase domain of PAK1 protein. The study, published in the American Journal of Medical Genetics: Part A, found potential correlations between how and which organ ...
Downregulation of angulin-1/LSR induces malignancy in lung adenocarcinoma
2023-03-29
“In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.”
BUFFALO, NY- March 29, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.”
Abnormal expression of bicellular tight junction claudins, including ...